To date, none of the next-generation PI3K/mTOR pathway inhibitors has been evaluated specifically in children, although preclinical studies of many of these drugs are ongoing in childhood leukemias with the goal of swift clinical translation (20, 74). This evidence concerns the gene PIK3CD and leukemia.